LexPharma

We’re heading to Chicago for the #AAN Annual Meeting! Lexicon will be onsite engaging with the neurology community and our SVP of Discovery, Suma Gopinathan, PhD, will lead two presentations on our investigational AAK1 inhibitor. Learn more: index.mirasmart.com/AAN2026/Search… #AANAM

We were pleased to sponsor and join industry peers at the 2026 Texas Life Sciences Summit, connecting with leaders and innovators helping shape the future of life sciences. We left encouraged by the momentum across the industry and energized about the opportunities ahead!

SCORED trial data were presented at #ACC26, including an analysis examining heart failure and cardiovascular outcomes across BMI categories in adults with type 2 diabetes and chronic kidney disease.

New insights from #ACC26. Dr. Juan Badimon shared Chapter 2 data from the SOTA‑P‑CARDIA trial, building on prior findings in people with HFpEF. Watch the presentation: reachmd.com/clinical-pract…

We’re heading to @ACCinTouch this week, where data from Lexicon’s clinical programs will be presented in oral and poster sessions, including analyses from the SCORED and SOTA‑P‑CARDIA studies. Learn more: investors.lexpharma.com/news-releases/…

@NovoNordisk has initiated a Phase 1 clinical study of LX9851, marking continued progress following our 2025 license agreement. Learn more: investors.lexpharma.com/news-releases/…

Chronic pain, including DPNP, doesn’t get the attention it deserves. Dr. Webster’s article advances the conversation on expanding treatment options. He previously joined Lexicon’s Chronic Pain Roundtable on non‑opioid innovation. Read more: painnewsnetwork.org/stories/2026/3…

Last November at #AHA Scientific Sessions, Dr. Juan Badimon shared clinical data on our SGLT1/2 inhibitor in HFpEF without diabetes. HFpEF affects over half of the nearly 7M Americans living with heart failure. Explore Chapter 1: reachmd.com/clinical-pract… Chapter 2 coming soon!

At #ATTD2026, we shared a new post hoc analysis of clinical data demonstrating the effect of our SGLT1/2 inhibitor after one year in T1D patients with varying kidney function. We’re proudly working to advance new treatment options for those in the T1D community.

We’re excited to be at the @ATTDconf in Barcelona this week! Our team will present data on how kidney function impacts the long-term safety & efficacy of our SGLT1/2 inhibitor in type 1 diabetes. Learn more: investors.lexpharma.com/news-releases/…

Yesterday we celebrated #InternationalWomensDay and the incredible women at Lexicon and beyond who drive healthcare forward. This year’s #GivetoGain theme reminds us that gender equity grows when women have equal opportunities, especially in STEM.

We’re proud to present Lexicon’s fourth quarter 2025 financial results and provide a clinical update. Learn more: linkedin.com/posts/mike-ext…

Our team has a big week ahead: fireside chat at the Leerink Partners Global Healthcare Conference, plus investor meetings at the @BarclaysBankUS 28th Global Healthcare Conference and @Jefferies Biotech on the Beach. Learn more: investors.lexpharma.com/news-releases/…

A recent Lexicon study is featured on the Journal of the Endocrine Society homepage, exploring ACSL5 as a biological target being studied in obesity and chronic weight management. Read more: academic.oup.com/jes/article/10…

We were honored to celebrate #HCMAwarenessDay with the Hypertrophic Cardiomyopathy Association at yesterday’s Open House. Raising awareness starts with listening and learning, and we’re grateful for the opportunity to connect with the HCM community. #KnowHCM

Next week, Lexicon will report our fourth quarter financial results along with a comprehensive business update. Conference call details can be found here: lexiconpharma.gcs-web.com/news-releases/…

Today we stand with the hypertrophic cardiomyopathy (HCM) patient community to raise awareness of this genetic heart condition. Those with HCM urgently need new treatment options, and at Lexicon, we’re working daily to make this possible!

February is #AmericanHeartMonth. Cardiac arrest is a leading cause of death, yet only ~41% of people receive bystander CPR. We support @American_Heart’s mission to double out-of-hospital cardiac arrest survival. For more: heart.org/en/american-he…

Today we recognize the #WomeninScience who drive breakthroughs that transform clinical care. As Rosalind Franklin famously said, “science and everyday life cannot and should not be separated.” We are grateful for the many women whose curiosity continues to drive innovation.

This weekend, the Lexicon team will be at the @ADA_DiabetesPro Clinical Update Conference! We’re looking forward to connecting with others helping to advance care for people living with type 1 diabetes and obesity.